Journal
CANCER LETTERS
Volume 356, Issue 2, Pages 347-356Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.10.045
Keywords
Adeno-associated virus; Cancer; Cancer gene therapy; Gene vehicle
Categories
Funding
- National Basic Research Program of China (973 Program) [2014CB744505]
- US National Institutes of Health [R01EB012467]
- Natural Science Foundation of China [81401504, 81430040]
- Program for National Science and Technology Major Project of China [2013ZX10002004-001-005]
- Medical Science and Technology Project of Zhejiang Province [201461368]
- Qianjiang Talent Program of Zhejiang Province in China [2012R10027]
- Scientific Research Foundation of the Health Bureau of Zhejiang Province in China [WKJ2012-2-030]
- Fundamental Research Funds for the Central Universities [2012QNA7037]
- SRF for ROCS, SEM
Ask authors/readers for more resources
Gene therapy is one of the frontiers of modern medicine. Adeno-associated virus (AAV)-mediated gene therapy is becoming a promising approach to treat a variety of diseases and cancers. AAV-mediated cancer gene therapies have rapidly advanced due to their superiority to other gene-carrying vectors, such as the lack of pathogenicity, the ability to transfect both dividing and non-dividing cells, low host immune response, and long-term expression. This article reviews and provides up to date knowledge on AAV-mediated cancer gene therapy. Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
